Financing ·
Enliven Therapeutics raises up to $432.4M in equity offering at $37.50 per share
ELVNEnliven Therapeutics, Inc.
Enliven Therapeutics, Inc. entered into an underwriting agreement on June 11, 2026, to issue and sell 8,933,334 shares of common stock at $37.50 per share and 1,733,333 pre-funded warrants at $37.499 per warrant. The offering is expected to close on June 15, 2026, with expected net proceeds of approximately $376.0 million, potentially increasing to $432.4 million if underwriters exercise their option to purchase an additional 1,600,000 shares. Enliven Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer and other diseases.